Wegovy HD: the top of the dose curve — and what it implies about the bottom

Published August 10, 2026 · Microdose GLP One editorial team · figures verified against publishers’ own pages

The news, verified: on March 19, 2026 the FDA approved Wegovy HD — semaglutide 7.2 mg weekly, triple the previous maximum — for adults with obesity who have tolerated 2.4 mg for at least four weeks, via an accelerated 54-day review. STEP UP results: about 20.7% average weight loss at 72 weeks, with 31.2% of participants losing a quarter of their body weight or more. Cash price through NovoCare: $399 a month, a $50 step over the $349 standard pens. For a site about lower doses, the interesting part is what the top of the curve proves about the whole curve.

Dose-response is real, and it runs both ways. HD's approval is the cleanest demonstration yet that semaglutide's effect scales with dose: 2.4 mg averages roughly 15%, 7.2 mg averages roughly 20%, and the price of the extra effect was paid in tolerability — dose reductions in 18.5% of the 7.2 mg group versus 12.4% at 2.4 mg, plus a distinctive altered-skin-sensation signal (dysesthesia in about one in five). Read downward, the same curve says what this site has always said about microdosing: lower doses mean, on average, less effect. There is no free lunch at either end — only trade-offs a prescriber can position you on deliberately.

What HD changes for the microdosing conversation: three things. First, the escalation label (must tolerate 2.4 mg first) formalizes the idea that dose is a supervised, stepwise variable — the same logic that makes a supervised step-down for maintenance coherent, and ad-hoc self-microdosing incoherent. Second, several clinicians already frame HD as a finite push — escalate to goal, then return to a lower maintenance dose — which quietly makes maintenance-dose strategy, this site's core topic, part of the mainstream playbook. Third, the pricing ladder now runs $149 (oral pill entry) → $349 (standard pens) → $399 (HD), bracketing the compounded microdose floor of roughly $129–189 from above and forcing the honest question: at those gaps, is the compounded microdose case about money, or about an individualized dose an approved product does not offer? Only the second survives scrutiny.

The unchanged rules: there is still no FDA-approved microdosing regimen for semaglutide at any strength; the landmark trials tested the standard ladders; and insurance, where it covers Wegovy — HD rides the same label — beats every cash figure here. Full pricing context lives in what microdosing costs in 2026 and the real cost of compounded GLP-1s.

Questions people ask

Sources & references

• Novo Nordisk — FDA approves Wegovy HD (Mar 19, 2026)
• Healio — FDA approves high-dose Wegovy 7.2 mg; STEP UP results and safety detail
• NovoCare — published cash pricing for Wegovy products
• Our maintenance-dose evidence review

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.